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Cytarabine, the 4-amino-1-(β-D-arabinofuranosyl)-2(1H)-
pyrimidinone, (ARA-C) is an antimetabolite cytidine 
analogue used worldwide as key drug in the management 
of leukaemia. As specified in the manufacturers’ 
instructions, once the components—sterile water and 
cytarabine powder—are unpackaged and mixed, the 
solution begins to degrade after 6 hours at room 
temperature and 12 hours at 4°C. To evaluate how to 
avoid wasting the drug in short-term, low-dose treatment 
regimens, the reconstituted samples, stored at 25°C and 
4°C, were analyzed every day of the test week by reversed-
phase HPLC and high-field NMR spectroscopy. All the 
samples remained unchanged for the entire week, which 
corresponds to the time required to administer the entire 
commercial drug package during low-dose therapeutic 
regimens. The drug solution was stored in a glass 
container at 4°C in an ordinary freezer and drawn with 
sterile plastic syringes; during this period, no bacterial 
or fungal contamination was observed. Our findings 
show that an cytarabine solution prepared and stored in 
the original vials retains its efficacy and safety and can, 
therefore, be divided into small doses to be administered 
over more days, thus avoiding unnecessary expensive 
and harmful waste of the drug preparation. Moreover, 
patients who require daily administration of the drug 
could undergo the infusion at home without need to go to 
hospital. The stability of the aliquots would help decrease 
hospitalization costs. Anti-Cancer Drugs XXX:000–000 
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Introduction
Cytarabine (ARA-C) (1, Fig. 1) is used worldwide for the 
management of leukaemia in children and adults [1]. 
Particularly, pediatric and adult acute and lymphoblastic 
myeloid leukaemia, lymphomas, adult myelodysplastic 
syndromes require ARA-C treatments [2]. The WHO’s 
List of Essential Medicines includes ARA-C among the 
most important medications needed in a basic health sys-
tem [3,4], the American Society of Clinical Oncology has 
stressed the crucial importance of this drug, while the 
USA Food Drug Administration recently announced a 
world shortage of its availability in the near future. Taken 
together, all these aspects underline the importance of a 
sparing use of this drug. Nonetheless, a remarkable waste 
does take place in the treatment of acute lymphoblastic 
leukaemia in children, where ARA-C is administrated 
subcutaneously in small daily doses. At children’s hos-
pitals, during the induction phase (1b) of acute lymph-
oblastic leukaemia, children undergo four 4-day cycles 
of ARA-C (75  mg/sqm/d in monoadministration v. or 
s.c., on days 38–41, 45–48, 52–55, 59–62). Small aliquots 
of ARA-C must be administered subcutaneously as pal-
liative treatment of acute myeloid leukaemia [5,6] and, 
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according to the commercial indications for the correct 
use of ARA-C, a new solution should be prepared every 
day [5,6]. Patients should go to hospital for a subcutaneous 
injection almost everyday, which has a negative impact 
on their compliance, quality of life, and family organiza-
tion [7]. Accordingly, the remainder of the unused solu-
tion should be discharged and disposed of as hazardous 
waste, with additional costs. To avoid these drawbacks, 
optimize drug usage and improve clinical management, 
a study on the short-term stability (one week, i.e., the 
maximum time required for the consumption of a whole 
pack) of ARA-C, that is, was performed.
The rationale of our previous study[4] was to define the 
stability of the bortezomib molecule beyond an 8-hour 
interval; the purpose was to avoid discarding the resid-
ual drug not administered within the interval speci-
fied. It is worth underlining that, in 2003, the cost of a 
3.5 mg vial of bortezomib was 1060 €, that is, 302.85 €/mg. 
Considering that, on average, patients were given 1.5 mg, 
the remaining 2 mg were discarded. The analyses carried 
out in our previous study showed the absence of degra-
dation molecules in bortezomib resuspended for a week 
after its reconstitution and no evidence of contamination. 
This allowed us to employ the remaining drug on other 
patients, beyond the 8-hour interval suggested by the 
producers, remarkably cutting down costs for bortezomib.
A similar analysis carried out for citosine arabinoside—the 
object of this report—was also aimed to define the safety 
of using the reconstituted residual drug, which should be 
discarded after the initial use.
Noteworthy, ARA-C used to be provided by the national 
health system upon medical prescription and was availa-
ble in pharmacies for home administration to patients who 
required only small subcutaneous injections. This proved 
to be feasible and practical for hundreds of patients refer-
ring to Italian hematology units, with no evidence in the 
literature of any drawback. Following the institution 
of the so-called Unità Manipolazione Chemioterapici 
Antiblastici: Antiblastic chemotherapy modulation units 
in Italy, these drugs are now only administered in hospital 
setting. Patients who, for years, could avail themselves of 
home treatment must now go to hospital for the admin-
istration of ARA-C, obviously overburdening the health 
care system.
Based on sound experience in several countries, many 
years may pass before reliable data (in terms of efficacy and 
safety) in the literature are gathered on large case series of 
patients treated in a given way, with a given drug adminis-
tered in a given way, and the instruction label is modified.
Inevitably, in common and sound clinical practice and in 
the patient’s best interest (should he/she reflect the case 
series described), the physician may disregards some of 
the indications in the instruction label. The physician’s 
approach, in this case, may be defined as ‘off-label.’
As a result of what stated above, this adaptation, in all 
safety—as it is based on data available in the literature 
[8,9] or, as in our case, on evidence from reliable labora-
tory tests—should more properly be defined as ‘awaiting 
label adjustment.’
ARA-C is an antimetabolite analogue of cytidine, a syn-
thetic nucleoside. It differs from the normal nucleosides 
deoxycytidine (2) and cytidine (3) in that the sugar moi-
ety is arabinose (Fig. 1).
Arabinose plays an important role in the mechanism of 
action of ARA-C, since the C-2′-hydroxyl group, in trans 
to the C-3′-hydroxyl group of the sugar, causes steric hin-
drance to the rotation of the pyrimidine base around the 
nucleoside bond. Whereas the nucleotide triphosphate 
(ARA-CTP) is incorporated at the terminal position of a 
growing DNA chain, it dramatically inhibits DNA syn-
thesis [10–12]. This makes ARA-C a powerful antitumor 
agent, able to interfere with physiological molecules due 
to its structural affinity with the cytidine nucleoside and 
Fig. 1
Structural formulas of cytarabine, physiological cytarabine-analogues. Deoxycytidine, cytidine and uracil arabinoside, a degradation product of 
cytarabine.
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its antiproliferative activity exerted at nanomolar concen-
trations (i.e. human leukaemia cell lines CCRF-CEM, 
IC
50
 = 6.30 nm). As aminoglycoside, the chemical and 
microbiological stability of ARA-C in its pharmaceutical 
form, after reconstitution and storage, could be affected 
by the hydrolysis of the amine group and the N-glycoside 
bond. The change in the sugar feature could be due to 
chemical and bacterial factors. As reported in the litera-
ture, both the d- and l-enantiomeric forms of the pentose 
sugar arabinose undergo chemical transformations under 
acidic condition or in the presence of degradating micro-
organisms that use some pentoses, hexoses, oligosac-
charides, and polysaccharides as sole carbon and energy 
source [10].
Moreover, some microorganisms as those of the 
Lactobacillus species, during their growth in media, can 
secrete some metabolites that alter the pH of the medium, 
contributing to hydrolyze the hemiaminal bond [11,12].
Cytidine is also reported to be largely deaminated to the 
therapeutically inactive 1-β-d-arabinosyluracil ARA-U 
(4) merely on recrystallization from water [13–17]. This 
reaction is explained in terms of an addition-elimination 
mechanism where the α,β-unsaturated system of the 
pyrimidine ring would be expected to facilitate water 
attacks (Fig. 2). The reaction may proceed via the simple 
addition of water on the N4-protonated base. A similar 
deamination of guanine and adenine residues in DNA is 
much slower, occurring at only 2–3% the rate of cytosine 
deamination [15].
In the light of the available evidence, an in-depth study 
by reversed-phase HPLC (RP-UHPLC) and high-field 
1H NMR was performed on commercial ARA-C samples 
to explore whether the pharmaceutical solution prepared 
is able to retain[18,19] the physical, therapeutic, and 
microbial properties limitedly to the week required for 
small-dose therapeutic regimens.
Methods
All chemicals were purchased from Sigma Aldrich (Milan, 
Italy). ARA-C is commercialized by numerous companies 
around the world; in Italy, it is distributed by Pfizer under 
the tradename Aracytin and is administrated as intra-
venous bolus or subcutaneous injection. The product 
information states that reconstituted ARA-C (100 mg of 
lyophilized ARA-C in 5 ml of sterile water) is stable for 6 
hours when stored at 25°C and for 12 hours at 4°C.
Our experiments were conducted using this product 
dissolved in the sterile water provided by the commer-
cial company (samples A) and in deuterated water (D
2
O, 
99.99% Merck) (samples B) to investigate, respectively 
by RP-UHPLC and NMR, the stability of the solution 
stored at 4°C. Each experiment was performed in trip-
licate and the spectral data were recorded every day for 
one week.
1Hand 13C NMR spectra were recorded at 500 MHz on 
a Fourier Transform NMR Varian 500 Unity Inova spec-
trometer. Chemical shifts are reported in δ values (ppm) 
and J values are reported in Hz.
RP-UHPLC analyses were performed on a Shimadzu 
Nexera UHPLC system (Shimadzu, Milano, Italy), con-
sisting of a CBM-20A controller, two LC-30AD dual-
plunger parallel-flow pumps, a DGU-20 A5 degasser, an 
SPDM20A photodiode array detector (equipped with a 
semi-micro flow cell of 2.5 μl), a CTO-20A column oven, 
a SIL-30 AC autosampler. The column employed in this 
study was a Synergi Fusion-RP 80 Å 150 × 4.6 mm, 4 μm 
(Phenomenex, Bologna, Italy). For RP-UHPLC anal-
yses, the mobile phase employed was (A) 0.1% TFA in 
water v/v and (B) 0.1% TFA in ACN v/v. The analysis 
was performed with the following gradient elution: 0–15 
minutes, 0% B; 15–17 minutes, 95% B and 17–20%, 0% B. 
Column oven temperature was set to 25°C and 5 μl of the 
sample were injected. The chromatogram was monitored 
at 245 and 260 nm at the two-absorbance maxima of the 
compound investigated.
Moreover, after a week, the samples used for the HPLC 
and NMR measurements underwent ESI-MS analyses 
by direct infusion (Fig. 3). A hybrid mass spectrometer 
Q-TOF Premier (Waters) composed of a single quadru-
pole, a collision cell and a mass analyzer of flight time 
were used. The nebulizing gas N
2
 was set to 300 L/h at 
Fig. 2
Hydrolysis of ARA-C cytosine moiety yielding the carbonyl uracil derivative (ARA-U, 4). ARA-C, cytarabine.
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a temperature of 210°C, operating in positive mode. The 
cone gas was set to a flow rate of 100 L/h, while source 
temperature was set at 90°C. The tensions of the capil-
lary and cone were fixed at 3 kV and 30 V, respectively. 
The mass range TOF for data collection was set between 
80 and 300 m/z. The Q-TOF Premier was set in V mode 
with an 8500 resolution, a scan time of 0.3 seconds and 
interscan delay of 0.02 seconds. Mass and composition 
of the ions were calculated using the MassLynx 4.1 and 
Elementar Composition.
Concerning the microbiological assays sterility was tested 
using the following culture media: Fluid Thioglycolate 
Medium (Becton Dickinson) supplemented with hemin 
and vitamin K1, to grow aerobic microaerophile and anaer-
obic microorganisms, including strict anaerobes; tryptic 
soy broth with casein extract (TSB, Becton Dickinson) 
to grow common aerobic and facultative anaerobic micro-
organisms[20,21]; solid media on plates: trypticase soy 
agar supplemented with 5% sheep blood (AS, Becton 
Dickinson); agar Schaedler supplemented with vitamin 
K1 and 5% sheep blood (SCH, Becton Dickinson); agar 
Sabouraud with dextrose + gentamycin + chloramphen-
icol (SAB, Becton Dickinson); chocolate agar + growth 
supplement for Hemophilus, Neisseria, Streptococcus 
pneumoniae culture (Biomerieux).
Four ARA-C vials from the same lot, stored at 4°C, 
were reconstituted according to the manufacturers’ 
instructions.
Every day of the test week, 0.5 ml of solution were drawn 
from each of the four vials, with a sterile syringe. The 
2  ml of solution sampled were used to verify its steril-
ity. In detail, 1 ml of sample was inoculated into 5 ml of 
FTM broth supplemented with vitamin K and hemin, 
subsequently incubating the solution for 7 days at 35 ± 
2°C in aerobic atmosphere; 1 ml of sample was inoculated 
in 5  ml of TSB broth and the solution incubated for 7 
days at 20–25°C in aerobic atmosphere. At the end of the 
incubation period, 30 µl of each culture in liquid medium 
Fig. 3
TOF-MS spectra of Aracytin Pfizer Cytarabine sample after one week.
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was inoculated on a solid medium (AS, SAB, SCH, choc-
olate agar); the subcultures were incubated for 3 days at 
35 ± 2°C under appropriate atmospheric conditions: AS 
and SAB in aerobiosis, SCH in an anaerobic atmosphere 
generator pouch (Becton Dickinson), and chocolate agar 




Solutions A and B were stored at 4°C and 25°C; they 
were tested every day for one week using 1H NMR and 
RP-UHPLC (Fig.  4), respectively, and no differences 
were detected between the initial and the final stages. To 
provide a complete assignments of the 1H NMR spec-
trum, we performed 1D as well as 2D experiments (1H-
1H COSY, NOESY); likewise, carbon signals were then 
attributed by means of one-bond and long-range 1H-13C 
hetero-correlated 2D-NMR spectra (HSQC and HMBC). 
In details, the 1H NMR spectrum showed interalia, the 
H-6 and H-5 protons of the cytosine moiety, as well as the 
H-1′ proton of the arabinose core in the low field region 
at δ 7.70, 5.92, and 6.06, respectively. The other protons 
were identified by chemical shifts at higher fields, thus 
at δ 4.25, 3.98, 3.87, 3.78, and 3.70, respectively, for H-2′, 
H-3′, H-4′, H-5′a, and H-5′b.
According to this evidence, the stored ARA-C seemed 
stable at 25°C as well as at 4°C.
At the end of incubation period, the microbiological anal-
yses on the liquid culture medium inoculated with drug 
aliquots failed to detect any turbidity, and the subcul-
tures on solid culture medium had no evidence of bac-
terial growth.
Therefore, the results of the sterility tests can be consid-
ered satisfactory, given the lack of microbial contamina-
tion in the specimen taken from each vial stored a 4°C 
for seven days.
Our findings provide evidence of an optimal physico-
chemical stability and microbiological sterility of ARA-C 
solution stored for one week at 4°C. This encourages the 
use of the reconstituted drug for the time required for 
short-term multidose treatments, avoiding drug waste, 
patient stress, and hospital crowding. Moreover, it seems 
possible to leave in the same container the surplus of dif-
ferent ARA-C packages, improving the cost-effectiveness 
of the treatment without affecting its efficacy and safety. 
An additional advantage is the fact that patients are able 
to have the treatment administered at home.
Fig. 4
Chromatograms of Aracytin Pfizer Cytarabine sample at 245 and 260 nm, in water solution after one week.
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Our results show that a solution of reconstituted ARA-C 
could be employed for a longer period than what sug-
gested by the manufacturers. In fact, patients could 
receive a safe aliquot to be used at home for short-term 
treatments, thus optimizing the use of aliquot residues 
and avoiding vial manipulation and the production of 
special waste material.
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